SCHEMBL21268785

SCHEMBL21268785

Cc1ccccc1N1CCN(c2cc3c(ccn3[Si](C(C)C)(C(C)C)C(C)C)cn2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3A P46098 1/20 0.40
▸ LMNA P02545 3/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ ADRB1 P08588 1/20 0.36
▸ TSHR P16473 3/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ MCOLN3 Q8TDD5 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ GPR35 Q9HC97 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21268752 0.78 HRH3 (0.39) HTR3ALMNAHSP90AA1GAAMAPT
SCHEMBL21268779 0.75 HTR7 (0.42) HTR3A
SCHEMBL21268744 0.70 HTR3A (0.45) HTR3ALMNAHSP90AA1GAAMAPT
SCHEMBL21268767 0.68 CDC7 (0.43) KMT2A
SCHEMBL4291189 0.66 ADRB1 (0.72) LMNAADRB1TSHRMCOLN3SMN1; SMN2
SCHEMBL15963196 0.66 MAPT (0.69) HTR3ALMNAGAAMAPTADRB1
SCHEMBL29236 0.63 SLC6A2 (0.41) CYP1A2SMN1; SMN2
SCHEMBL5097575 0.63 HTR6 (0.49) HTR3AGAAMAPTSMN1; SMN2KDM4E
SCHEMBL21281585 0.63 PARP1 (0.44) HTR3ALMNAHSP90AA1GAAMAPT
SCHEMBL4306537 0.63 HTR6 (0.50) HTR3ALMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200399268-A1 Pharmaceutical 6,5 Heterobicyclic Ring Derivatives EVOTEC (UK) LTD (GB) 2020-12-24 — — US disclosed
EP-3752150-A1 PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES UCB Biopharma SRL (BE) 2020-12-23 — — EP disclosed
WO-2019158731-A1 PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-08-22 — — WO disclosed
EP-3527209-A1 PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES UCB Biopharma SPRL (BE) 2019-08-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399268-A1 Pharmaceutical 6,5 Heterobicyclic Ring Derivatives STING1, IRF3, NFATC1 HTR3A 3352/4885LMNA 445/4885HSP90AA1 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback